Clinical, molecular, and genetic characteristics of the hereditary spastic paraplegia type 3
Introduction. The autosomal dominant hereditary spastic paraplegia type 3 (SPG3), associated with the ATL1 gene, is a common form of the hereditary spastic paraplegia (HSP). The molecular genetic and clinical features of the SPG3 have not been sufficiently studied. Study aim: to conduct the first...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Research Center of Neurology
2020-03-01
|
| Series: | Анналы клинической и экспериментальной неврологии |
| Subjects: | |
| Online Access: | https://annaly-nevrologii.com/journal/pathID/article/viewFile/636/506 |
| _version_ | 1818217173977399296 |
|---|---|
| author | Galina E. Rudenskaya Varvara A. Kadnikova Christian Beetz Tatyana N. Proskokova Irina G. Sermyagina Anna A. Stepanova Valery P. Fedotov Elena L. Dadaly Darya M. Guseva Тatiana V. Markova Oksana P. Ryzhkova |
| author_facet | Galina E. Rudenskaya Varvara A. Kadnikova Christian Beetz Tatyana N. Proskokova Irina G. Sermyagina Anna A. Stepanova Valery P. Fedotov Elena L. Dadaly Darya M. Guseva Тatiana V. Markova Oksana P. Ryzhkova |
| author_sort | Galina E. Rudenskaya |
| collection | DOAJ |
| description | Introduction. The autosomal dominant hereditary spastic paraplegia type 3 (SPG3), associated with the ATL1 gene, is a common form of the hereditary spastic paraplegia (HSP). The molecular genetic and clinical features of the SPG3 have not been sufficiently studied.
Study aim: to conduct the first clinical, molecular, and genetic study of HSP in Russia, using a high-throughput exome sequencing technology massively parallel sequencing (MPS).
Materials and methods. Study subject: 14 identified families with SPG3. Clinical and molecular genetic methods used: Sanger sequencing, MPS panel for spastic paraplegia, multiplex ligation-dependent probe amplification.
Results. SPG3 made up 7.2% of the 195 examined families, 13.6% of 103 molecularly identified cases, and 16.9% of the dominant forms, coming in second place after SPG4 (50%). We found 9 missense mutations in 14 families (7 in hot exons), with 4 new ones and the known p.Arg415Trp mutation identified in 4 families. One case was caused by a de novo mutation, the others were familial; incomplete penetrance was found in 5 families (subclinical cases). Gender distribution of the probands was equal, but there were more males among the affected relatives. Most of the 25 examined patients, as well as the relatives with clinical data, had early-onset (in the first decade of life, often at the age of 1 to 3 years), uncomplicated HSP with slow progression; many of those subjects were initially diagnosed with a cerebral palsy. Subclinical axonal polyneuropathy was found in 3 out of 6 cases using EMG. Atypical severe paraparesis was combined with skeletal pathology (likely independent of the major condition) in one female patient. Intellectual disability in males of another family was also considered to be an independent condition.
Conclusion. SPG3 has a significant prevalence among HSP in Russian patients. The clinical features in most cases are similar and relatively non-severe; clinical diagnosis may be challenging, especially in non-familial and non-apparent familial (incomplete penetrance) cases, as well as when combined with other conditions. An incorrect diagnosis of cerebral palsy is often made. A verified diagnosis is necessary for genetic counselling and is important for patient management. MPS methods are the most informative in the molecular genetic diagnosis of HSP. |
| first_indexed | 2024-12-12T07:03:40Z |
| format | Article |
| id | doaj.art-cb785b6c298746ea89b96a7bb419e2f1 |
| institution | Directory Open Access Journal |
| issn | 2075-5473 2409-2533 |
| language | English |
| last_indexed | 2024-12-12T07:03:40Z |
| publishDate | 2020-03-01 |
| publisher | Research Center of Neurology |
| record_format | Article |
| series | Анналы клинической и экспериментальной неврологии |
| spelling | doaj.art-cb785b6c298746ea89b96a7bb419e2f12022-12-22T00:33:48ZengResearch Center of NeurologyАнналы клинической и экспериментальной неврологии2075-54732409-25332020-03-01141445410.25692/ACEN.2020.1.5485Clinical, molecular, and genetic characteristics of the hereditary spastic paraplegia type 3Galina E. Rudenskaya0Varvara A. Kadnikova1Christian Beetz2Tatyana N. Proskokova3Irina G. Sermyagina4Anna A. Stepanova5Valery P. Fedotov6Elena L. Dadaly7https://orcid.org/0000-0001-5602-2805Darya M. Guseva8Тatiana V. Markova9Oksana P. Ryzhkova10Research Centre for Medical GeneticsResearch Centre for Medical GeneticsCentogene AGFar-Eastern State Medical UniversityResearch Centre for Medical GeneticsResearch Centre for Medical GeneticsVoronezh Regional Clinical Hospital No. 1Research Centre for Medical GeneticsResearch Centre for Medical GeneticsResearch Centre for Medical GeneticsResearch Centre for Medical GeneticsIntroduction. The autosomal dominant hereditary spastic paraplegia type 3 (SPG3), associated with the ATL1 gene, is a common form of the hereditary spastic paraplegia (HSP). The molecular genetic and clinical features of the SPG3 have not been sufficiently studied. Study aim: to conduct the first clinical, molecular, and genetic study of HSP in Russia, using a high-throughput exome sequencing technology massively parallel sequencing (MPS). Materials and methods. Study subject: 14 identified families with SPG3. Clinical and molecular genetic methods used: Sanger sequencing, MPS panel for spastic paraplegia, multiplex ligation-dependent probe amplification. Results. SPG3 made up 7.2% of the 195 examined families, 13.6% of 103 molecularly identified cases, and 16.9% of the dominant forms, coming in second place after SPG4 (50%). We found 9 missense mutations in 14 families (7 in hot exons), with 4 new ones and the known p.Arg415Trp mutation identified in 4 families. One case was caused by a de novo mutation, the others were familial; incomplete penetrance was found in 5 families (subclinical cases). Gender distribution of the probands was equal, but there were more males among the affected relatives. Most of the 25 examined patients, as well as the relatives with clinical data, had early-onset (in the first decade of life, often at the age of 1 to 3 years), uncomplicated HSP with slow progression; many of those subjects were initially diagnosed with a cerebral palsy. Subclinical axonal polyneuropathy was found in 3 out of 6 cases using EMG. Atypical severe paraparesis was combined with skeletal pathology (likely independent of the major condition) in one female patient. Intellectual disability in males of another family was also considered to be an independent condition. Conclusion. SPG3 has a significant prevalence among HSP in Russian patients. The clinical features in most cases are similar and relatively non-severe; clinical diagnosis may be challenging, especially in non-familial and non-apparent familial (incomplete penetrance) cases, as well as when combined with other conditions. An incorrect diagnosis of cerebral palsy is often made. A verified diagnosis is necessary for genetic counselling and is important for patient management. MPS methods are the most informative in the molecular genetic diagnosis of HSP.https://annaly-nevrologii.com/journal/pathID/article/viewFile/636/506spg3atl1 gene mutationhigh-throughput exon sequencingmpsincomplete penetranceclinical picturecombination of diseases |
| spellingShingle | Galina E. Rudenskaya Varvara A. Kadnikova Christian Beetz Tatyana N. Proskokova Irina G. Sermyagina Anna A. Stepanova Valery P. Fedotov Elena L. Dadaly Darya M. Guseva Тatiana V. Markova Oksana P. Ryzhkova Clinical, molecular, and genetic characteristics of the hereditary spastic paraplegia type 3 Анналы клинической и экспериментальной неврологии spg3 atl1 gene mutation high-throughput exon sequencing mps incomplete penetrance clinical picture combination of diseases |
| title | Clinical, molecular, and genetic characteristics of the hereditary spastic paraplegia type 3 |
| title_full | Clinical, molecular, and genetic characteristics of the hereditary spastic paraplegia type 3 |
| title_fullStr | Clinical, molecular, and genetic characteristics of the hereditary spastic paraplegia type 3 |
| title_full_unstemmed | Clinical, molecular, and genetic characteristics of the hereditary spastic paraplegia type 3 |
| title_short | Clinical, molecular, and genetic characteristics of the hereditary spastic paraplegia type 3 |
| title_sort | clinical molecular and genetic characteristics of the hereditary spastic paraplegia type 3 |
| topic | spg3 atl1 gene mutation high-throughput exon sequencing mps incomplete penetrance clinical picture combination of diseases |
| url | https://annaly-nevrologii.com/journal/pathID/article/viewFile/636/506 |
| work_keys_str_mv | AT galinaerudenskaya clinicalmolecularandgeneticcharacteristicsofthehereditaryspasticparaplegiatype3 AT varvaraakadnikova clinicalmolecularandgeneticcharacteristicsofthehereditaryspasticparaplegiatype3 AT christianbeetz clinicalmolecularandgeneticcharacteristicsofthehereditaryspasticparaplegiatype3 AT tatyananproskokova clinicalmolecularandgeneticcharacteristicsofthehereditaryspasticparaplegiatype3 AT irinagsermyagina clinicalmolecularandgeneticcharacteristicsofthehereditaryspasticparaplegiatype3 AT annaastepanova clinicalmolecularandgeneticcharacteristicsofthehereditaryspasticparaplegiatype3 AT valerypfedotov clinicalmolecularandgeneticcharacteristicsofthehereditaryspasticparaplegiatype3 AT elenaldadaly clinicalmolecularandgeneticcharacteristicsofthehereditaryspasticparaplegiatype3 AT daryamguseva clinicalmolecularandgeneticcharacteristicsofthehereditaryspasticparaplegiatype3 AT tatianavmarkova clinicalmolecularandgeneticcharacteristicsofthehereditaryspasticparaplegiatype3 AT oksanapryzhkova clinicalmolecularandgeneticcharacteristicsofthehereditaryspasticparaplegiatype3 |